摘要
心血管疾病(CVD)是慢性肾脏病(CKD)患者最常见的并发症,且CVD又是CKD患者主要的死亡原因之一,而血管钙化是CVD发生的独立危险因素。CKD血管钙化是以心血管结构中磷酸钙以羟基磷灰石晶体的形式沉积为特征的病理学改变,其可导致管壁增厚和异位钙化。无机磷酸盐(PI)的转运是调节PI稳态和钙化过程的主要因素,PI受甲状旁腺激素和1,25-二羟基维生素D的调节。焦磷酸盐(PPI)是一种体内外强有力的抑制磷酸钙沉积的内源性抑制剂,血管钙化抑制剂的合成是细胞抑制血管钙化的主要机制。本文就PI的稳态、转运,PPI的代谢及PPI与CKD患者血管钙化的关系等作一综述,以期为这些患者开辟新的治疗选择。
Cardial vessel disease(CVD)is the most common complication of patients with chronic kidney disease(CKD),CVD is one of the leading causes of death in patients with CKD,while vascular calcification is an independent risk factor for CVD.Vascular calcification in CKD is a pathological change characterized by the deposition of calcium phosphate in the form of hydroxyapatite crystals in the cardiovascular structure,which can lead to tube wall thickening and ectopic calcification.Inorganic phosphate(PI)transport is a major factor regulating PI homeostasis and calcification,and PI is regulated by parathyroid hormone and 1,25-dihydroxyvitamin D.Pyrophosphate(PPI)is an intrinsic inhibitor of calcium phosphate deposition in vitro and in vivo.The synthesis of vascular calcification inhibitors is the main mechanism by which cells inhibit vascular calcification.This article reviews the homeostasis and transport of PI,the metabolism of PPI,and the relationship between vascular calcification in PPI and CKD patients,in order to open up new treatment options for these patients.
作者
马宁
刘玲
MA Ning;LIU Ling(Department of Nephrology,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)
出处
《中国当代医药》
2019年第29期22-24,30,共4页
China Modern Medicine
关键词
焦磷酸盐
磷酸盐
血管钙化
慢性肾脏病
Pyrophosphate
Phosphate
Vascular calcification
Chronic kidney disease
